| Date | Title | Description |
| 08.08.2024 | Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update | — First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 —
— KB-9558 IND-enabling studies for multiple myeloma remain o... |
| 07.03.2024 | Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway | - |
| 05.03.2024 | Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting | - |
| 17.08.2022 | Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML | Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML
Entospletinib is currently being studied in the Phase 3 AGIL... |
| 11.05.2021 | KRONOS BIO, INC.
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day | Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform
Preclinical data for KB-0742 presented at the American Association for Ca... |
| 26.01.2021 | News briefing: Nestlé whips up research collaboration with newly-unveiled Flagship upstart; Marianne De Backer joins Kronos board | Flagship Pioneering tapped into a variety of trendy R&D themes when it officially debuted Senda Biosciences a few months ago, most prominently its focus on the microbiome, computational biology and cellular i... |
| 25.08.2020 | Kronos Bio Raises $155 Million In Private Financing | Kronos Bio announced private financing of about $155 million of convertible notes with $148 million in funding received to date and the remaining $7 million to be funded by mid-September pursuant to binding commitments
Kronos Bio – a privat... |
| 24.08.2020 | Kronos Bio Raises $155M in Private Financing | Kronos Bio, Inc., a San Mateo, Calif.- and Cambridge, Mass.-based clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics, raised approximately $155m of convertible notes.
$148 millio... |
| 24.08.2020 | Kronos Bio Announces $155 Million Private Financing | - |
| 24.08.2020 | Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year | Perceptive Advisors led the financing, which included funds managed by, affiliated or otherwise associated with with BlackRock, Casdin Partners, Commodore Capital, EcoR1 Capital, Fidelity Management and Research Company, Surveyor Capital, T... |
| 24.08.2020 | Kronos Bio announces $155 million private financing for the discovery and development of novel cancer therapeutics | Kronos Bio, a Silicon Valley-based clinical-stage biopharmaceutical startup dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets, today announced private financing of a... |
| 24.08.2020 | Kronos Bio Announces $155 Million Private Financing | SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes t... |
| 07.08.2019 | Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D. | SAN MATEO, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–August 7, 2019–
Kronos Bio, Inc., a Two River portfolio company, today announced the appointment of Roger D. Kornberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Kornberg, a r... |
| 24.07.2019 | Biomedical Innovation Company Kronos Bio Raises $105 Million | Kronos Bio — a biomedical innovation company known for its Small Molecule Microarray platform (SMM) — announced it raised $105 million in funding
Kronos Bio announced it has raised $105 million in Series A funding — which was co-led by Vida... |
| 18.07.2019 | Kronos Bio Completes $105 Million Series A Financing | - |
| 18.07.2019 | Kronos Bio bags $105M in Series A round for platform technology | The company is part of the portfolio of New York-based venture capital firm Two River, whose portfolio also includes Allogene Therapeutics, led by Belldegrun and fellow Kite alumnus David Chang.
Kronos’ platform is called Small Molecule Mic... |
| 18.07.2019 | Vida Ventures Co-Leads $105 Million Series A Financing for Kronos Bio | BOSTON--(BUSINESS WIRE)--Vida Ventures, LLC (Vida), a next-generation life sciences venture firm, today announced that it co-led the $105 million Series A financing round for Kronos Bio (Kronos). Vida played a prominent role as a seed inves... |
| 18.07.2019 | Kronos Bio Completes $105 Million Series A Financing | Series A Round Led by Vida Ventures and Omega Funds
Company Platform Using Small Molecule Microarray (SMM) Technology has the Potential to Unlock Historically Undruggable Targets
SAN MATEO, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–July... |
| 18.07.2019 | Vida Ventures Co-Leads $105 Million Series A Financing for Kronos Bio | - |
| 18.07.2019 | Kronos Bio Secures $105M |
BOSTON, MA, Vida Ventures, a next-generation life sciences venture firm, today announced that it co-led the $105 million Series A financing round for Kronos Bio.
>> Click here for more funding data on Kronos
>> To export Kro... |
| 18.07.2019 | Kronos Bio Closes $105M Series A Financing | Kronos Bio, a San Mateo, Calif. & Cambridge, Mass.-based company dedicated to the discovery and development of first-in-class therapies that modulate historically undruggable targets, closed a $105m Series A financing.
The round was led... |
| 27.11.2018 | Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities | CAMBRIDGE, Mass.–(BUSINESS WIRE)–November 27, 2018–
Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced that it has appointed Philip Gutry as its Chief Business Officer. In this newly created role, Philip will drive th... |
| 02.10.2018 | FierceBiotech Names Kronos Bio As One of Its “Fierce 15” Biotech Companies of 2018 | CAMBRIDGE, Mass.–(BUSINESS WIRE)–October 2, 2018–
Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of... |
| 07.08.2018 | Which New York City healthcare companies raised the most dough from investors in Q2? | Thrive Global, the consumer wellness platform headed up by Arianna Huffington, was at the top of the list. In May, it announced it brought in $43 million.
Aetion, which focuses on real-world data through the science and analytics platform i... |
| 24.05.2018 | Term Sheet — Thursday, May 24 | BIG BET
Big news out of the daily fantasy sports world.
Paid Content You can't secure what you can't see From ExtraHop
Under the agreement, Paddy Power will merge its U.S. assets with FanDuel and provide a further $158 million in cash. The ... |
| 23.05.2018 | Kronos Bio Receives $18M Seed Round |
CAMBRIDGE, MA, Kronos Bio, (Kronos), a Two River portfolio company, today announced the completion of an $18 million seed financing.
>> Click here for more funding data on Kronos Bio
>> To export Kronos Bio funding data to P... |
| 23.05.2018 | Kronos Bio Appoints Dr. Norbert Bischofberger as CEO and Completes $18 Million Seed Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced the appointment of Norbert Bischofberger, Ph.D. as its President and Chief Executive Officer and completion of an $18 million seed ... |
| 23.05.2018 | Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing | - |
| 23.05.2018 | Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing | Strategic Seed Investors Include Kite Pharma Founder, Arie Belldegrun, M.D., FACS, Chairman of Gilead Sciences, John Martin, Ph.D., Norbert Bischofberger, Ph.D., Omega Funds and Vida Ventures
CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 23, 2018–
K... |
| - | Kronos Bio bags $105M in Series A round for platform technology | The latest early-stage venture capital mega round has gone to one of a growing crop of companies exploring “undruggable” drug targets.
San Mateo, California-based Kronos Bio said Thursday that it had closed a $105 million Series A funding r... |
| - | Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year | A startup planning to enter a blood cancer drug into late-stage clinical development next year has raised more than $150 million in a private financing.
San Mateo, California-based Kronos Bio said Monday that it had raised the $155 million ... |
| - | Which New York City healthcare companies raised the most dough from investors in Q2? | A new report from New York City Health Business Leaders found that during the second quarter of 2018, investors poured more than $300 million into healthcare startups based in the Big Apple.
The investment update also provides a closer look... |
